-
Liquid Biopsy: An Emerging Diagnostic, Prognostic, and Predictive Tool in Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2024-1-16 Hye Sook Han, Keun-Wook Lee
Liquid biopsy, a minimally invasive procedure that causes minimal pain and complication risks to patients, has been extensively studied for cancer diagnosis and treatment. Moreover, it facilitates comprehensive quantification and serial assessment of the whole-body tumor burden. Several biosources obtained through liquid biopsy have been studied as important biomarkers for establishing early diagnosis
-
Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond. J. Gastric Cancer (IF 2.5) Pub Date : 2024-1-16 In-Ho Kim
In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel
-
Current Issues in Reduced-Port Gastrectomy: A Comprehensive Review. J. Gastric Cancer (IF 2.5) Pub Date : 2024-1-16 Jong Won Kim
Reduced-port gastrectomy (RPG) includes all procedures derived from various efforts to minimize surgical invasiveness, with single-incision laparoscopic gastrectomy (SILG) being the ultimate reduced-port technique. However, there are challenges related to its feasibility, oncological validity, training, and education. This review describes the current issues and challenges, as well as the future prospects
-
Unusual or Uncommon Histology of Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2024-1-16 Jinho Shin, Young Soo Park
This review comprehensively examines the diverse spectrum of gastric cancers, focusing on unusual or uncommon histology that presents significant diagnostic and therapeutic challenges. While the predominant form, tubular adenocarcinoma, is well-characterized, this review focuses on lesser-known variants, including papillary adenocarcinoma, micropapillary carcinoma, adenosquamous carcinoma, squamous
-
Unveiling the Gastrointestinal Microbiome Symphony: Insights Into Post-Gastric Cancer Treatment Microbial Patterns and Potential Therapeutic Avenues. J. Gastric Cancer (IF 2.5) Pub Date : 2024-1-16 Chan Hyuk Park
This review delved into the intricate relationship between the gastrointestinal microbiome and gastric cancer, particularly focusing on post-treatment alterations, notably following gastrectomy, and the effects of anticancer therapies. Following gastrectomy, analysis of fecal samples revealed an increased presence of oral cavity aerotolerant and bile acid-transforming bacteria in the intestine. Similar
-
Risk Factors of Gastric Cancer and Lifestyle Modification for Prevention. J. Gastric Cancer (IF 2.5) Pub Date : 2024-1-16 Kwang-Pil Ko
Gastric cancer has been consistently decreasing worldwide, whereas cardia gastric cancer is on the rise. This indicates that the exposure rates to epidemiological causes are changing. In this study, we aim to review the risk factors for gastric cancer with respect to cardia and non-cardia types. One of the most significant risk factors for gastric cancer is Helicobacter pylori infection. H. pylori
-
Endoscopic Intervention for Anastomotic Leakage After Gastrectomy. J. Gastric Cancer (IF 2.5) Pub Date : 2024-1-16 Ji Yoon Kim, Hyunsoo Chung
Anastomotic leaks and fistulas are significant complications of gastric surgery that potentially lead to increased postoperative morbidity and mortality. Surgical intervention is reserved for cases with severe symptoms or hemodynamic instability; however, surgery carries a higher risk of complications. With advancements in endoscopic treatment options, endoscopic approaches have emerged as the primary
-
Endoscopic Treatment for Gastric Subepithelial Tumor. J. Gastric Cancer (IF 2.5) Pub Date : 2024-1-16 Chan Gyoo Kim
Most gastric subepithelial tumors (SETs) are asymptomatic and are often incidentally discovered during endoscopic procedures conducted for unrelated reasons. Although surveillance is sufficient for the majority of gastric SETs, certain cases necessitate proactive management. Laparoscopic wedge resection, although a viable treatment option, has its limitations, particularly in cases where SETs (especially
-
Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study. J. Gastric Cancer (IF 2.5) Pub Date : 2023-10-01 Keitaro Shimozaki,Izuma Nakayama,Daisuke Takahari,Kengo Nagashima,Koichiro Yoshino,Koshiro Fukuda,Shota Fukuoka,Hiroki Osumi,Mariko Ogura,Takeru Wakatsuki,Akira Ooki,Eiji Shinozaki,Keisho Chin,Kensei Yamaguchi
PURPOSE Determination of optimal treatment strategies for HER2-positive advanced gastric cancer (AGC) in randomized trials is necessary despite difficulties in direct comparison between trastuzumab deruxtecan (T-DXd) and nivolumab as third or later-line treatments. MATERIALS AND METHODS This single-institution, retrospective study aimed to describe the real-world efficacy and safety of T-DXd and nivolumab
-
Journal of Gastric Cancer: Navigating the Future With the KGCA Guidelines and Nationwide Surveys. J. Gastric Cancer (IF 2.5) Pub Date : 2023-10-01 Ki Bum Park,Han Hong Lee
-
Worse Survival of Patients With T1 Stage II Gastric Cancer Following Radical Gastrectomy. J. Gastric Cancer (IF 2.5) Pub Date : 2023-10-01 Hayemin Lee,Kyo Young Song,Han Hong Lee,Junhyun Lee
PURPOSE Lymph node (LN) metastasis is a crucial factor in the prognosis of patients with gastric cancer (GC) and is known to occur more frequently in cases with an advanced T stage. This study aimed to analyze the survival data of patients with advanced LN metastasis in T1 GC. MATERIALS AND METHODS From January 2008 to June 2018, 677 patients with pathological stage II GC who underwent radical gastrectomy
-
The Impact of Different Types of Complications on Long-Term Survival After Total Gastrectomy for Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2023-10-01 Mi Ran Jung,Sung Eun Kim,Oh Jeong
PURPOSE This study aimed to investigate the impact of different types of complications on long-term survival following total gastrectomy for gastric cancer. MATERIALS AND METHODS A total of 926 patients who underwent total gastrectomy between 2008 and 2016 were included. Patients were divided into the morbidity and no-morbidity groups, and long-term survival was compared between the 2 groups. The prognostic
-
Indications for Dental Floss Clip Traction During Gastric Endoscopic Submucosal Dissection by Less-Experienced Endoscopists. J. Gastric Cancer (IF 2.5) Pub Date : 2023-10-01 Hirosato Tamari,Shiro Oka,Takahiro Kotachi,Hajime Teshima,Junichi Mizuno,Motomitsu Fukuhara,Hidenori Tanaka,Akiyoshi Tsuboi,Ken Yamashita,Ryo Yuge,Yuji Urabe,Yasuhiko Kitadai,Koji Arihiro,Shinji Tanaka
PURPOSE Dental floss clip (DFC) traction-assisted endoscopic submucosal dissection (ESD) is widely performed owing to its simplicity. This study aimed to clarify the appropriate indications for the DFC traction method in early gastric cancer when ESD is performed by less-experienced endoscopists. METHODS AND METHODS We retrospectively analyzed 1,014 consecutive patients who had undergone gastric ESD
-
Long-term Functional and Patient-reported Outcomes Between Intra-corporeal Delta-shaped Gastroduodenostomy and Gastrojejunostomy After Laparoscopic Distal Gastrectomy. J. Gastric Cancer (IF 2.5) Pub Date : 2023-10-01 Sin Hye Park,Hong Man Yoon,Keun Won Ryu,Young-Woo Kim,Mira Han,Bang Wool Eom
PURPOSE This study aimed to compare the long-term functional and patient-reported outcomes between intra-corporeal delta-shaped gastroduodenostomy and gastrojejunostomy after laparoscopic distal gastrectomy for gastric cancer. MATERIALS AND METHODS We retrospectively reviewed clinicopathological data from 616 patients who had undergone laparoscopic distal gastrectomy for stage I gastric cancer between
-
Impact of Coronavirus Disease 2019 on Gastric Cancer Diagnosis and Stage: A Single-Institute Study in South Korea. J. Gastric Cancer (IF 2.5) Pub Date : 2023-10-01 Moonki Hong,Mingee Choi,JiHyun Lee,Kyoo Hyun Kim,Hyunwook Kim,Choong-Kun Lee,Hyo Song Kim,Sun Young Rha,Gyu Young Pih,Yoon Jin Choi,Da Hyun Jung,Jun Chul Park,Sung Kwan Shin,Sang Kil Lee,Yong Chan Lee,Minah Cho,Yoo Min Kim,Hyoung-Il Kim,Jae-Ho Cheong,Woo Jin Hyung,Jaeyong Shin,Minkyu Jung
PURPOSE Gastric cancer (GC) is among the most prevalent and fatal cancers worldwide. National cancer screening programs in countries with high incidences of this disease provide medical aid beneficiaries with free-of-charge screening involving upper endoscopy to detect early-stage GC. However, the coronavirus disease 2019 (COVID-19) pandemic has caused major disruptions to routine healthcare access
-
Novel Clean End-to-End Anastomosis Method, Without Opening the Stomach Lumen, in Totally Laparoscopic or Robotic Pylorus-Preserving Gastrectomy. J. Gastric Cancer (IF 2.5) Pub Date : 2023-10-01 Takashi Mitsui,Kazuyuki Saito,Yuhei Hakozaki,Yoshiyuki Miwa,Takuji Noro,Emiko Takeshita,Taizen Urahashi,Yasuyuki Seto,Takashi Okuyama,Hideyuki Yoshitomi
PURPOSE Intra-abdominal infection is a common postoperative complication of laparoscopic pylorus-preserving gastrectomies (PPGs). Many studies have reported that intra-abdominal infectious complications after gastrectomy adversely affect patient survival outcomes. To prevent gastric fluid leakage into the abdominal cavity, we developed a novel anastomosis method in which the stomach lumen is not opened
-
The Shorr Versus Modified Ultrafast Papanicolaou Method for Intraoperative Diagnosis of Peritoneal Washing Cytology in Advanced Gastric Cancer: A Phase II Study. J. Gastric Cancer (IF 2.5) Pub Date : 2023-10-01 So Hyun Kang,Hee Young Na,Younghwa Choi,Eunju Lee,Mira Yoo,Duyeong Hwang,Sa-Hong Min,Young Suk Park,Sang-Hoon Ahn,Yun-Suhk Suh,Do Joong Park,Hye Seung Lee,Hyung-Ho Kim
PURPOSE According to the American Joint Committee on Cancer cancer staging system, positive peritoneal washing cytology (PWC) indicates stage IV gastric cancer. However, rapid intraoperative diagnosis of PWC has no established reliable method. This study evaluated and compared the diagnostic accuracy of the Shorr and the modified ultrafast Papanicolaou (MUFP) methods for intraoperative PWC. MATERIALS
-
Real-World Compliance of Surgical Treatment According to the Korean Gastric Cancer Guideline 2018: Evaluation From the Nationwide Survey Data 2019 in Korea. J. Gastric Cancer (IF 2.5) Pub Date : 2023-10-01 Sang Soo Eom,Sin Hye Park,Bang Wool Eom,Hong Man Yoon,Young-Woo Kim,Keun Won Ryu
PURPOSE This study evaluated real-world compliance with surgical treatment according to Korea's gastric cancer treatment guidelines. MATERIALS AND METHODS The 2018 Korean Gastric Cancer Treatment Guidelines were evaluated using the 2019 national survey data for surgically treated gastric cancer based on postoperative pathological results in Korea. In addition, the changes in surgical treatments in
-
The Role of Artificial Intelligence in Gastric Cancer: Surgical and Therapeutic Perspectives: A Comprehensive Review. J. Gastric Cancer (IF 2.5) Pub Date : 2023-8-9 JunHo Lee, Hanna Lee, Jun-Won Chung
Stomach cancer has a high annual mortality rate worldwide necessitating early detection and accurate treatment. Even experienced specialists can make erroneous judgments based on several factors. Artificial intelligence (AI) technologies are being developed rapidly to assist in this field. Here, we aimed to determine how AI technology is used in gastric cancer diagnosis and analyze how it helps patients
-
Artificial Intelligence in Gastric Cancer Imaging With Emphasis on Diagnostic Imaging and Body Morphometry. J. Gastric Cancer (IF 2.5) Pub Date : 2023-8-9 Kyung Won Kim, Jimi Huh, Bushra Urooj, Jeongjin Lee, Jinseok Lee, In-Seob Lee, Hyesun Park, Seongwon Na, Yousun Ko
Gastric cancer remains a significant global health concern, coercing the need for advancements in imaging techniques for ensuring accurate diagnosis and effective treatment planning. Artificial intelligence (AI) has emerged as a potent tool for gastric-cancer imaging, particularly for diagnostic imaging and body morphometry. This review article offers a comprehensive overview of the recent developments
-
Artificial Intelligence in Surgery and Its Potential for Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2023-8-9 Takahiro Kinoshita, Masaru Komatsu
Artificial intelligence (AI) has made significant progress in recent years, and many medical fields are attempting to introduce AI technology into clinical practice. Currently, much research is being conducted to evaluate that AI can be incorporated into surgical procedures to make them safer and more efficient, subsequently to obtain better outcomes for patients. In this paper, we review basic AI
-
Artificial Intelligence in the Pathology of Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2023-8-9 Sangjoon Choi, Seokhwi Kim
Recent advances in artificial intelligence (AI) have provided novel tools for rapid and precise pathologic diagnosis. The introduction of digital pathology has enabled the acquisition of scanned slide images that are essential for the application of AI. The application of AI for improved pathologic diagnosis includes the error-free detection of potentially negligible lesions, such as a minute focus
-
Outcomes of Gastrectomy for Gastric Cancer in Patients Aged >80 Years: A Systematic Literature Review and Meta-Analysis. J. Gastric Cancer (IF 2.5) Pub Date : 2023-8-9 Zelalem Chimdesa Merga, Ji Sung Lee, Chung-Sik Gong
This meta-analysis examined the surgical management of older patients (>80 years) with gastric cancer, who were often excluded from randomized controlled trials. We analyzed 23 retrospective cohort studies involving 18,372 patients and found that older patients had a higher in-hospital mortality rate (relative risk [RR], 3.23; 95% confidence interval [CI], 1.46-7.17; P<0.01) and more post-operative
-
Efficacy and Safety of ClearCut™ Knife H-type in Endoscopic Submucosal Dissection for Gastric Neoplasms: A Multicenter, Randomized Trial. J. Gastric Cancer (IF 2.5) Pub Date : 2023-8-9 Eun Jeong Gong, Hyun Lim, Sang Jin Lee, Do Hoon Kim
Endoscopic submucosal dissection (ESD) is an effective treatment for early gastrointestinal neoplasms. However, this is a time-consuming procedure requiring various devices. This study aimed to evaluate the efficacy and safety of the ClearCut™ Knife H-type, which is an integrated needle-tipped and insulated-tipped (IT) knife.
-
Complication After Gastrectomy for Gastric Cancer According to Hospital Volume: Based on Korean Gastric Cancer Association-Led Nationwide Survey Data. J. Gastric Cancer (IF 2.5) Pub Date : 2023-8-9 Sang-Ho Jeong, Moon-Won Yoo, Miyeong Park, Kyung Won Seo, Jae-Seok Min
This study aimed to analyze the incidence and risk factors of complications following gastric cancer surgery in Korea and to compare the correlation between hospital complications based on the annual number of gastrectomies performed.
-
The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2023-8-9 Jae Yeon Jang, Youngkyung Jeon, Sun Young Jeong, Sung Hee Lim, Won Ki Kang, Jeeyun Lee, Seung Tae Kim
The optimal tumor mutational burden (TMB) value for predicting treatment response to programmed cell death-1 (PD-1) checkpoint inhibitors in advanced gastric cancer (AGC) remains unclear. We aimed to investigate the optimal TMB cutoff value that could predict the efficacy of PD-1 checkpoint inhibitors in AGC.
-
Feasibility and Potential of Reduced Port Surgery for Total Gastrectomy With Overlap Esophagojejunal Anastomosis Method. J. Gastric Cancer (IF 2.5) Pub Date : 2023-8-9 Ho Seok Seo, Sojung Kim, Kyo Young Song, Han Hong Lee
Reduced port surgery (RPS) for gastric cancer has been frequently reported in distal gastrectomies but rarely in total gastrectomies. This study aimed to determine the feasibility of 3-port totally laparoscopic total gastrectomy (TLTG) with overlapping esophagojejunal (EJ) anastomosis.
-
Comparison of Laparoscopic and Open Gastrectomy for Patients With Gastric Cancer Treated With Neoadjuvant Chemotherapy: A Multicenter Retrospective Study Based on the Korean Gastric Cancer Association Nationwide Survey. J. Gastric Cancer (IF 2.5) Pub Date : 2023-8-9 Seul Ki Oh, Chang Seok Ko, Seong-A Jeong, Jeong Hwan Yook, Moon-Won Yoo, Beom Su Kim, In-Seob Lee, Chung Sik Gong, Sa-Hong Min, Na Young Kim
Despite scientific evidence regarding laparoscopic gastrectomy (LG) for advanced gastric cancer treatment, its application in patients receiving neoadjuvant chemotherapy remains uncertain.
-
A Nomogram for Predicting Extraperigastric Lymph Node Metastasis in Patients With Early Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2023-04-01 Hyun Joo Yoo,Hayemin Lee,Han Hong Lee,Jun Hyun Lee,Kyong-Hwa Jun,Jin-Jo Kim,Kyo-Young Song,Dong Jin Kim
BACKGROUND There are no clear guidelines to determine whether to perform D1 or D1+ lymph node dissection in early gastric cancer (EGC). This study aimed to develop a nomogram for estimating the risk of extraperigastric lymph node metastasis (LNM). MATERIALS AND METHODS Between 2009 and 2019, a total of 4,482 patients with pathologically confirmed T1 disease at 6 affiliated hospitals were included in
-
Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study. J. Gastric Cancer (IF 2.5) Pub Date : 2023-04-01 Chunjing Wang,Zhen Wang,Yue Zhao,Fujing Wang
PURPOSE This study aimed to evaluate the efficacy and safety of neoadjuvant programmed cell death-1 (PD-1) inhibitors plus apatinib and chemotherapy (PAC) in patients with locally advanced gastric cancer (LAGC). MATERIALS AND METHODS Seventy-three patients with resectable LAGC were enrolled and named the PAC group (n=39) or apatinib plus chemotherapy (AC) group (n=34) based on the treatment they chose
-
Fatty Acid Binding Protein 5 (FABP5) Promotes Aggressiveness of Gastric Cancer Through Modulation of Tumor Immunity. J. Gastric Cancer (IF 2.5) Pub Date : 2023-04-01 Mei-Qing Qiu,Hui-Jun Wang,Ya-Fei Ju,Li Sun,Zhen Liu,Tao Wang,Shi-Feng Kan,Zhen Yang,Ya-Yun Cui,You-Qiang Ke,Hong-Min He,Shu Zhang
PURPOSE Gastric cancer (GC) is the second most lethal cancer globally and is associated with poor prognosis. Fatty acid-binding proteins (FABPs) can regulate biological properties of carcinoma cells. FABP5 is overexpressed in many types of cancers; however, the role and mechanisms of action of FABP5 in GC remain unclear. In this study, we aimed to evaluate the clinical and biological functions of FABP5
-
Advantages of Function-Preserving Gastrectomy for Older Patients With Upper-Third Early Gastric Cancer: Maintenance of Nutritional Status and Favorable Survival. J. Gastric Cancer (IF 2.5) Pub Date : 2023-04-01 Masayoshi Terayama,Manabu Ohashi,Satoshi Ida,Masaru Hayami,Rie Makuuchi,Koshi Kumagai,Takeshi Sano,Souya Nunobe
PURPOSE The incidence of early gastric cancer is increasing in older patients alongside life expectancy. For early gastric cancer of the upper third of the stomach, laparoscopic function-preserving gastrectomy (LFPG), including laparoscopic proximal gastrectomy (LPG) and laparoscopic subtotal gastrectomy (LSTG), is expected to be an alternative to laparoscopic total gastrectomy (LTG). However, whether
-
Comprehensive Study of Microsatellite Instability Testing and Its Comparison With Immunohistochemistry in Gastric Cancers. J. Gastric Cancer (IF 2.5) Pub Date : 2023-04-01 Yujun Park,Soo Kyung Nam,Soo Hyun Seo,Kyoung Un Park,Hyeon Jeong Oh,Young Suk Park,Yun-Suhk Suh,Sang-Hoon Ahn,Do Joong Park,Hyung-Ho Kim,Hye Seung Lee
PURPOSE In this study, polymerase chain reaction (PCR)-based microsatellite instability (MSI) testing was comprehensively analyzed and compared with immunohistochemistry (IHC) for mismatch repair (MMR) protein expression in patients with gastric cancer (GC). MATERIALS AND METHODS In 5,676 GC cases, PCR-based MSI testing using five microsatellites (BAT-26, BAT-25, D5S346, D2S123, and D17S250) and IHC
-
Chylous Ascites After Gastric Cancer Surgery: Risk Factors and Treatment Results. J. Gastric Cancer (IF 2.5) Pub Date : 2023-04-01 Sung Hyun Park,Ki-Yoon Kim,Minah Cho,Hyoung-Il Kim,Woo Jin Hyung,Yoo Min Kim
PURPOSE Although chylous ascites is a frequent complication of radical gastrectomy for gastric cancer, proper diagnostic criteria and optimal treatment strategies have not been established. This study aimed to identify the clinical features of chylous ascites and evaluate the treatment outcomes. MATERIALS AND METHODS We retrospectively analyzed the data of patients who underwent radical gastrectomy
-
Effect of Four Main Gastrectomy Procedures for Proximal Gastric Cancer on Patient Quality of Life: A Nationwide Multi-Institutional Study. J. Gastric Cancer (IF 2.5) Pub Date : 2023-04-01 Koji Nakada,Akitoshi Kimura,Kazuhiro Yoshida,Nobue Futawatari,Kazunari Misawa,Kuniaki Aridome,Yoshiyuki Fujiwara,Kazuaki Tanabe,Hirofumi Kawakubo,Atsushi Oshio,Yasuhiro Kodera
PURPOSE This study aimed to examine the effects of 4 main types of gastrectomy for proximal gastric cancer on postoperative symptoms, living status, and quality of life (QOL) using the Postgastrectomy Syndrome Assessment Scale-45 (PGSAS-45). MATERIALS AND METHODS We surveyed 1,685 patients with upper one-third gastric cancer who underwent total gastrectomy (TG; n=1,020), proximal gastrectomy (PG; n=518)
-
A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation. J. Gastric Cancer (IF 2.5) Pub Date : 2023-04-01 Guk Jin Lee,Hyunho Kim,Sung Shim Cho,Hyung Soon Park,Ho Jung An,In Sook Woo,Jae Ho Byun,Ji Hyung Hong,Yoon Ho Ko,Der Sheng Sun,Hye Sung Won,Jong Youl Jin,Ji Chan Park,In-Ho Kim,Sang Young Roh,Byoung Yong Shim
PURPOSE Oxaliplatin, a component of the capecitabine plus oxaliplatin (XELOX) regimen, has a more favorable toxicity profile than cisplatin in patients with advanced gastric cancer (GC). However, oxaliplatin can induce sensory neuropathy and cumulative, dose-related toxicities. Thus, the capecitabine maintenance regimen may achieve the maximum treatment effect while reducing the cumulative neurotoxicity
-
Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study. J. Gastric Cancer (IF 2.5) Pub Date : 2023-04-01 Takatsugu Ogata,Yukiya Narita,Zev A Wainberg,Eric Van Cutsem,Kensei Yamaguchi,Yongzhe Piao,Yumin Zhao,Patrick M Peterson,Sameera R Wijayawardana,Paolo Abada,Anindya Chatterjee,Kei Muro
PURPOSE Liver metastasis (LM) is reported in approximately 40% of patients with advanced/metastatic gastric/gastroesophageal junction adenocarcinoma (metastatic esophagogastric adenocarcinoma; mGEA) and is associated with a worse prognosis. This post-hoc analysis from the RAINBOW trial reported the efficacy, safety, and biomarker outcomes of ramucirumab and paclitaxel combination treatment (RAM+PAC)
-
Clinical Implication of Liver Metastasis in the Treatment of Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2023-04-01 Chi Hoon Maeng
-
A Standardized Pathology Report for Gastric Cancer: 2nd Edition. J. Gastric Cancer (IF 2.5) Pub Date : 2023-2-9 Young Soo Park, Myeong-Cherl Kook, Baek-Hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi, Hee Kyung Chang, Soomin Ahn, Mee Soo Chang, Song-Hee Han, Yoonjin Kwak, An Na Seo, Sung Hak Lee, Mee-Yon Cho
The first edition of 'A Standardized Pathology Report for Gastric Cancer' was initiated by the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists and published 17 years ago. Since then, significant advances have been made in the pathologic diagnosis, molecular genetics, and management of gastric cancer (GC). To reflect those changes, a committee for publishing a second edition
-
Role of Adjuvant Radiotherapy in Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2023-2-9 Jeong Il Yu
Although continuous improvement in the treatment outcome of localized gastric cancer has been achieved through early screening, diagnosis, and treatment and the active application of surgery and adjuvant chemotherapy, the necessity of adjuvant radiotherapy (RT) remains controversial. In this review, based on the results of two recently published randomized phase III studies (Adjuvant Chemoradiation
-
Mediastinal Lymph Node Dissection in Gastroesophageal Junction Adenocarcinoma. J. Gastric Cancer (IF 2.5) Pub Date : 2023-2-9 Jin-Jo Kim
Currently, the prevalence of gastroesophageal junction adenocarcinoma (GEJAC) is increasing in both Asian and Western countries, although the increasing rate in Asian countries is much slower than in Western countries. With these current trends, concerns regarding the surgical treatment method are also increasing among gastrointestinal surgeons. However, the surgical treatment for GEJAC has been a
-
Recent Progress in Immunotherapy for Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2023-2-9 Jeesun Yoon, Tae-Yong Kim, Do-Youn Oh
Gastric cancer (GC) is the fourth leading cause of cancer-related deaths worldwide. Under the standard of care, patients with advanced GC (AGC) have a median survival time of approximately 12-15 months. With the emergence of immunotherapy as a key therapeutic strategy in medical oncology, relevant changes are expected in the systemic treatment of GC. In the phase III ATTRACTION-2 trial, nivolumab,
-
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach. J. Gastric Cancer (IF 2.5) Pub Date : 2023-2-9 Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung Sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im, Hye Seong Ahn, Hyun Lim, Hyung-Don Kim, Jae-Joon Kim, Jeong Il Yu, Jeong Won Lee, Ji Yeon Park, Jwa Hoon Kim, Kyoung Doo Song, Minkyu Jung, Mi Ran
Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this is the 4th gastric cancer guideline published in Korea which is the revised version of previous evidence-based approach in 2018. Current guideline is a collaborative work of the interdisciplinary working group including experts in the field of gastric surgery, gastroenterology, endoscopy, medical oncology, abdominal
-
Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination. J. Gastric Cancer (IF 2.5) Pub Date : 2023-2-9 Sun Young Rha, Hyun Cheol Chung
Gastric cancer is heterogeneous in morphology, biology, genomics, and treatment response. Alterations in human epidermal growth factor receptor 2 (HER2) overexpression, microsatellite instability (MSI) status, programmed death-ligand 1 (PD-L1) levels, and fibroblast growth factor receptor 2 (FGFR2) can be used as biomarkers. Since the combination of fluoropyrimidine/platinum plus trastuzumab that was
-
Endoscopic Resection of Undifferentiated Early Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2023-2-9 Yuichiro Hirai, Seiichiro Abe, Mai Ego Makiguchi, Masau Sekiguchi, Satoru Nonaka, Haruhisa Suzuki, Shigetaka Yoshinaga, Yutaka Saito
Endoscopic resection (ER) is widely performed for early gastric cancer (EGC) with a negligible risk of lymph node metastasis (LNM) in Eastern Asian countries. In particular, endoscopic submucosal dissection (ESD) leads to a high en bloc resection rate, enabling accurate pathological evaluation. As undifferentiated EGC (UD-EGC) is known to result in a higher incidence of LNM and infiltrative growth
-
Recent Advances in Sentinel Node Navigation Surgery for Early Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2023-2-9 Eisuke Booka, Hiroya Takeuchi
Maintaining the postoperative quality of life (QOL) while ensuring curability without overtreatment is important in the treatment of early gastric cancer. Postoperative QOL is anticipated to be maintained through minimally invasive function-preserving gastrectomy in early gastric cancer. The concept of the sentinel lymph node (SN) basin is essential to maintain the curability of early gastric cancer
-
Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2023-2-9 Xie Tong, Peng Zhi, Shen Lin
Presently, surgery is the only treatment approach for gastric cancer and improving the prognosis of locally advanced gastric cancer is one of the key factors in promoting gastric cancer survival benefit. The MAGIC study was the first to demonstrate the efficacy of neoadjuvant chemotherapy (NAC) in European countries. In recent years, several clinical trials have provided evidence for the use of NAC
-
A Big Step Forward in the New KGCA Guidelines. J. Gastric Cancer (IF 2.5) Pub Date : 2023-01-01 Sang-Yong Son,Sang-Uk Han
-
Molecular Pathology of Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2022-11-1 Moonsik Kim, An Na Seo
Gastric cancer (GC) is one of the most common lethal malignant neoplasms worldwide, with limited treatment options for both locally advanced and/or metastatic conditions, resulting in a dismal prognosis. Although the widely used morphological classifications may be helpful for endoscopic or surgical treatment choices, they are still insufficient to guide precise and/or personalized therapy for individual
-
Apatinib as a Third-Line Treatment for HER2-Positive Metastatic Gastric Cancer: A Multi-Center Single-Arm Cohort Study. J. Gastric Cancer (IF 2.5) Pub Date : 2022-11-1 Xin Zhang, Haoran Huo, Yanan Nie, Jiadong Xue, Zengjiang Yuan, Zhenyi Zhang
Treatment options are limited after the failure of first-and second-line treatments in patients with HER2+ metastatic gastric cancer (mGC). The present study aimed to explore the efficacy, safety, and prognostic factors of apatinib efficacy as a third-line therapy for patients with human epithelial growth factor receptor 2-positive (HER2+) mGC.
-
PLK2 Single Nucleotide Variant in Gastric Cancer Patients Affects miR-23b-5p Binding. J. Gastric Cancer (IF 2.5) Pub Date : 2022-11-1 Pia Pužar Dominkuš, Aner Mesic, Petra Hudler
Chromosomal instability is a hallmark of gastric cancer (GC). It can be driven by single nucleotide variants (SNVs) in cell cycle genes. We investigated the associations between SNVs in candidate genes, PLK2, PLK3, and ATM, and GC risk and clinicopathological features.
-
Tumor Location Causes Different Recurrence Patterns in Remnant Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2022-11-1 Bo Sun, Haixian Zhang, Jiangli Wang, Hong Cai, Yi Xuan, Dazhi Xu
Tumor recurrence is the principal cause of poor outcomes in remnant gastric cancer (RGC) after resection. We sought to elucidate the recurrent patterns according to tumor locations in RGC.
-
Safe Discharge Criteria After Curative Gastrectomy for Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2022-11-1 Ali Guner, Ki Yoon Kim, Sung Hyun Park, Minah Cho, Yoo Min Kim, Woo Jin Hyung, Hyoung-Il Kim
This study aimed to investigate the relationship between clinical and laboratory parameters and complication status to predict which patients can be safely discharged from the hospital on the third postoperative day (POD).
-
Endoscopic Findings and Treatment of Gastric Neoplasms in Familial Adenomatous Polyposis. J. Gastric Cancer (IF 2.5) Pub Date : 2022-11-1 Chihiro Sato, Kazuya Takahashi, Hiroki Sato, Takumi Naruse, Nao Nakajima, Masafumi Takatsuna, Ken-Ichi Mizuno, Satoru Hashimoto, Manabu Takeuchi, Junji Yokoyama, Masaaki Kobayashi, Shuji Terai
Gastric neoplasia is a common manifestation of familial adenomatous polyposis (FAP). This study aimed to elucidate the clinical characteristics, endoscopic features including fundic gland polyposis (FGPsis), and treatment outcomes of gastric neoplasms (GNs) in patients with FAP.
-
Sp1-Induced SETDB1 Overexpression Transcriptionally Inhibits HPGD in a β-Catenin-Dependent Manner and Promotes the Proliferation and Metastasis of Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2022-11-1 Yaguan Fan, Libo Yang, Yi Ren, Yunhua Wu, Linhai Li, Lihua Li
Gastric cancer (GC) has high morbidity and mortality, the cure rate of surgical treatment and drug chemotherapy is not ideal. Therefore, development of new treatment strategies is necessary. We aimed to identify the mechanism underlying Sp1 regulation of GC progression.
-
Extragastric Metastasis of Early Gastric Cancer After Endoscopic Submucosal Dissection With Lymphovascular Invasion and Negative Resected Margins. J. Gastric Cancer (IF 2.5) Pub Date : 2022-11-1 Han Myung Lee, Yoonjin Kwak, Hyunsoo Chung, Sang Gyun Kim, Soo-Jeong Cho
Lymphovascular invasion is a criterion for non-curative resection in patients who have undergone endoscopic submucosal dissection (ESD) for early gastric cancer (EGC). We aimed to determine the rate of extragastric metastasis (EGM) and identify the predictors of EGM in patients with negative resection margins (R0 resection) and lymphovascular invasion in post-ESD pathology.
-
Impact of the COVID-19 Pandemic on Gastric Cancer Screening in South Korea: Results From the Korean National Cancer Screening Survey (2017-2021). J. Gastric Cancer (IF 2.5) Pub Date : 2022-11-1 Kyeongmin Lee, Mina Suh, Jae Kwan Jun, Kui Son Choi
The coronavirus disease 2019 (COVID-19) pandemic has significantly disrupted cancer screening services worldwide. We aimed to measure the impact of COVID-19 on gastric cancer screening rates based on age, sex, household income, and residential area.
-
Urinary Biomarkers for the Noninvasive Detection of Gastric Cancer. J. Gastric Cancer (IF 2.5) Pub Date : 2022-11-1 Dehong Li, Li Yan, Fugui Lin, Xiumei Yuan, Xingwen Yang, Xiaoyan Yang, Lianhua Wei, Yang Yang, Yan Lu
Gastric cancer (GC) is associated with high morbidity and mortality rates. Thus, early diagnosis is important to improve disease prognosis. Endoscopic assessment represents the most reliable imaging method for GC diagnosis; however, it is semi-invasive and costly and heavily depends on the skills of the endoscopist, which limit its clinical applicability. Therefore, the search for new sensitive biomarkers
-
Decision for Safe Discharge After Gastric Cancer Surgery: The Finale of Enhanced Recovery After Surgery Program. J. Gastric Cancer (IF 2.5) Pub Date : 2022-10-01 Yoon Young Choi
-
Epidemiology of Gastric Cancer in Korea: Trends in Incidence and Survival Based on Korea Central Cancer Registry Data (1999-2019). J. Gastric Cancer (IF 2.5) Pub Date : 2022-8-9 Sin Hye Park, Mee Joo Kang, E Hwa Yun, Kyu-Won Jung
This study investigated the trends of gastric cancer in Korea by adding the latest updated gastric cancer data from 2019. Gastric cancer incidence between 1999 and 2019 was reviewed using data from the Korea Central Cancer Registry. The study period was divided into 3 periods: period I (1999-2005), period II (2006-2012), and period III (2013-2019). The incidence, mortality, tumor location, histology